DLL3 and small cell lung carcinoma: Another delta-like ligand 3 (DLL3)/CD3 BiTE targeting DLL3, IMDELLTRATM (tarlatamab-dlle), has completed phase I and II clinical trials (NCT03319940, NCT05060016) [127, 128], and has recently received accelerated approval from the U.S. Food and Drug Administration (FDA), becoming the first and only T cell engager for the treatment of extensive-stage Small-cell lung cancer (SCLC) [129].